Altimmune, Inc.

Good day, ladies and gentlemen, and welcome to Altamune Inc. Second Quarter 2024 Financial Results Conference Call. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. As a reminder, this call is being recorded. I would now like to introduce your host for today's conference call, Lee Roth of Burns McClellan Investor Relations Advisors to Altimmune. Lee, you may begin.

Thanks, Gigi. Good morning, everyone. Thank you for participating on the Altimmune Second Quarter 2024 Financial Results and Business Update Conference Call. Members of the Altimmune team joining me today are Vipin Garg, our Chief Executive Officer, Scott Harris, our Chief Medical Officer, Ray Jort, our Chief Business Officer, Andrew Shutterly, our Acting Chief Financial Officer, and Scott Roberts, our Chief Scientific Officer. Following prepared remarks from Vipin, Scott, Harris, and Andrew, we'll hold a Q&A session. As a reminder, a press release with our Q2 2024 financial results was issued this morning and can be found on the IR section of the company's website. Before we begin, I'd like to remind everyone that remarks about future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altamune cautions that these forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from those indicated. For discussion of some of the risks and the factors that could impact the company's future results and operations, please refer to the risk factors and other cautionary statements contained in our filings with the SEC. I'll also direct you to read the forward-looking statement disclaimer in our press release issued earlier today and now available on our website. Any statements made during this call speak only as of today's date, Thursday, August 8, 2024, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today. As a reminder, this call is being recorded and will be available for audio replay on the Altimmune website. With that, it's now my pleasure to turn the call over to Dr. Vipin Garg, Chief Executive Officer of Altimmune. Vipin?

Thanks, Lee. Good morning, everyone. And once again, thank you for joining us for our second quarter corporate update. In the second quarter and throughout the first half of the year, we continue to strengthen the rationale for pembidutide as a highly differentiated therapeutic with significant potential in a variety of metabolic diseases. We are continuing to advance our key strategic, clinical, and operational priorities that are excited for the milestones that are approaching in both our obesity and MASH programs. The quarter was highlighted by important data presentations at two of the most prominent medical meetings in our space, the American Diabetes Association or ADA's 84th Scientific Sessions, and the European Association for the Study of the Liver or EASL Congress. At the ADA meeting in June, we presented updated data on the effects of pembidutide on body composition from our phase two momentum obesity trial that demonstrated a class leading preservation of lean mass among increasing agents. Preservation of lean mass and the quality of weight loss is becoming increasingly important for the treatment of obesity and for the safety and long-term maintenance of weight loss. In addition, we presented data during the EASL Congress that highlighted the disease-modifying potential of pembidutide in MASH and reinforces our confidence in achieving both the MASH resolution and fibrosis endpoint in our Phase IIb impact trial. We remain engaged in discussions regarding a global strategic transaction for pembidutide involving a variety of possible structures. We are intently focused on identifying and securing a partner with the right vision, resources, and commitment to help us realize the full potential of pembidutide in obesity, MASH, and other metabolic conditions. In parallel, We intend to create additional value by completing the impact study and pursuing additional indications for which pembidutide is specially well suited. Finally, we continue to prepare for the end of phase two meeting with the FDA to review our registrational program for obesity. The outcome of this meeting will confirm the patient population we believe will benefit most from the differentiated profile of pembidutide. With that, I'll now turn the call over to our chief medical officer, Dr. Scott Harris, to provide additional updates and discuss our plans. Scott. Thank you, Vipin.